IDXX IDEXX Laboratories, Inc.
Healthcare$559.14+0.00%OpenMarket Cap: $44.11B
As of 2026-05-26
Valuation
P/E (TTM)
42.31
PEG
2.19
P/B
28.79
P/S
9.92
EV/EBITDA
29.60
DCF Value
$174.76
FCF Yield
2.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
62.1%
Operating Margin
31.6%
Net Margin
24.6%
ROE
70.9%
ROA
32.4%
ROIC
40.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $1.14B | 63.4% | $362.6M | $278.4M | $— | — |
| Q4 null | $1.09B | 60.3% | $315.6M | $248.2M | $— | — |
| FY null | $4.30B | 61.8% | $1.36B | $1.06B | $— | — |
| Q3 null | $1.11B | 61.8% | $354.8M | $274.6M | $— | — |
| Q2 null | $1.11B | 62.6% | $373.0M | $294.0M | $— | — |
| Q1 null | $998.4M | 62.4% | $316.5M | $242.7M | $— | — |
| Q4 null | $954.3M | 59.8% | $261.7M | $216.1M | $— | — |
| FY null | $3.90B | 61.0% | $1.13B | $887.9M | $— | — |
| Q3 null | $975.5M | 61.1% | $303.9M | $232.8M | $— | — |
| Q2 null | $1.00B | 61.9% | $263.8M | $203.3M | $— | — |
| Q1 null | $964.1M | 61.5% | $299.0M | $235.6M | $— | — |
| Q4 2023 | $901.6M | 58.4% | $245.3M | $194.5M | $2.32 | — |